Loading...
Docoh

Johnson & Johnson (JNJ)

Johnson & Johnson believes good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for more than 130 years, Johnson & Johnson has aimed to keep people well at every age and every stage of life. Today, as the world’s largest and most broadly-based healthcare company, Johnson & Johnson is committed to using its reach and size for good. Johnson & Johnson strives to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. Johnson & Johnson is blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

Company profile

Ticker
JNJ
Exchange
Website
CEO
Alex Gorsky
Employees
Incorporated
Location
Fiscal year end
Former names
JOHNSON & JOHNSON ET AL
SEC CIK
Subsidiaries
Acclarent, Inc. • Actelion Pharmaceuticals US, Inc. • Akros Medical, Inc. • Albany Street LLC • ALZA Corporation • Alza Land Management, Inc. • AMO Development, LLC • AMO Manufacturing USA, LLC • AMO Nominee Holdings, LLC • AMO Sales and Service, Inc. ...
IRS number
221024240

JNJ stock data

Investment data

Data from SEC filings
22 long holdings
End of quarter 30 Jun 22
Value
 
#Shares
 
Prev Q
 
Change
%, QoQ
$89.61M 1.63M 1.63M 0
$83.73M 3.38M 3.38M 0
$44.4M 1.26M 1.26M 0
$33.29M 1.02M 1.02M 0
$21.94M 2.9M 2.9M 0
$21.01M 3.5M 3.5M 0
$20.47M 748.06K 748.06K 0
$19.37M 2.45M 2.45M 0
$17.76M 5.55M 5.55M 0
$10.64M 728.94K 728.94K 0
$9.14M 3.67M 3.67M 0
$6.81M 1M 1M 0
$5.34M 1.07M 1.07M 0
$2.17M 192.43K 192.43K 0
$1.58M 394.83K 394.83K 0
$1.56M 2.13M 2.13M 0
$1.27M 281.05K 281.05K 0
$964K 1.61M 1.61M 0
$168K 84K 84K 0
$119K 66.95K 66.95K 0
$56K 54.62K 54.62K 0
$54K 49.55K 49.55K 0
Holdings list only includes long positions. Only includes long positions.

Calendar

29 Jul 22
19 Aug 22
1 Jan 23
Quarter (USD) Jul 22 Apr 22 Jan 22 Oct 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Jan 22 Jan 21 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 10.98B 10.98B 10.98B 10.98B 10.98B 10.98B
Cash burn (monthly) (no burn) 279.08M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) n/a 438.61M n/a n/a n/a n/a
Cash remaining n/a 10.54B n/a n/a n/a n/a
Runway (months of cash) n/a 37.8 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
10 Jun 22 Kathryn E Wengel Common Stock Sell Dispose S No No 173.001 33,126 5.73M 71,310.874
10 Jun 22 Kathryn E Wengel Common Stock Sell Dispose S No No 173.001 6,600 1.14M 104,436.874
10 Jun 22 Kathryn E Wengel Common Stock Sell Dispose S No No 173.001 174 30.1K 111,036.874
10 Jun 22 Kathryn E Wengel Common Stock Sell Dispose S No No 173.001 100 17.3K 111,210.874
10 Jun 22 Kathryn E Wengel Common Stock Option exercise Acquire M No No 72.54 40,000 2.9M 111,310.874
10 Jun 22 Kathryn E Wengel Employee Stock Options Common Stock Option exercise Dispose M No No 72.54 40,000 2.9M 16,410
7 Jun 22 Marillyn A Hewson Deferred Share Units Common Stock Grant Acquire A No No 177.25 230.65 40.88K 5,651.967
7 Jun 22 Weinberger Mark A Deferred Share Units Common Stock Grant Acquire A No No 177.25 239.797 42.5K 5,774.386
7 Jun 22 Washington A. Eugene Deferred Share Units Common Stock Grant Acquire A No No 177.25 348.969 61.85K 27,432.88
26 May 22 Robert J Decker Common Stock Sell Dispose S No No 180 8,462 1.52M 15,473
67.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 3499 3557 -1.6%
Opened positions 124 166 -25.3%
Closed positions 182 137 +32.8%
Increased positions 1530 1611 -5.0%
Reduced positions 1469 1403 +4.7%
13F shares Current Prev Q Change
Total value 313.39B 316.18B -0.9%
Total shares 1.77B 1.79B -1.2%
Total puts 11.78M 11.16M +5.5%
Total calls 14.73M 16.11M -8.6%
Total put/call ratio 0.8 0.7 +15.4%
Largest owners Shares Value Change
Vanguard 242.53M $43.05B +1.8%
BLK Blackrock 205.4M $36.46B +2.3%
STT State Street 141.08M $25.04B -0.8%
Geode Capital Management 46.71M $8.28B +3.7%
MS Morgan Stanley 37.92M $6.73B +45.8%
NTRS Northern Trust 33.86M $6.01B -0.6%
BAC Bank Of America 33.22M $5.9B +10.4%
BK Bank Of New York Mellon 32.03M $5.69B -0.1%
State Farm Mutual Automobile Insurance 31.68M $5.62B 0.0%
JPM JPMorgan Chase & Co. 30.41M $5.4B +17.4%
Largest transactions Shares Bought/sold Change
LGEN Legal & General 0 -18.42M EXIT
MS Morgan Stanley 37.92M +11.9M +45.8%
Parametric Portfolio Associates 0 -11.36M EXIT
Arrowstreet Capital, Limited Partnership 29.85K -6.62M -99.6%
Fisher Asset Management 5.73M +5.09M +797.8%
BLK Blackrock 205.4M +4.6M +2.3%
JPM JPMorgan Chase & Co. 30.41M +4.5M +17.4%
Vanguard 242.53M +4.38M +1.8%
CFS Investment Advisory Services 22.47K -3.97M -99.4%
TROW T. Rowe Price 24.62M +3.91M +18.9%

Financial report summary

?
Risks
  • The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
  • Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
  • The Company relies on third parties to manufacture certain of our products. Any failure by or loss of a third-party manufacturer could result in delays and increased costs, which may adversely affect our business.
  • Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.
  • The COVID-19 pandemic has adversely impacted certain aspects of the Company’s business and could cause disruptions or future impact to the Company’s business, results of operations and financial condition.
  • Global sales in the Company’s Pharmaceutical and Medical Devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
  • The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
  • Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
  • The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
  • Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
  • The Company faces increased challenges to intellectual property rights central to its business.
  • Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
  • Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.
  • The planned separation of the Company’s Consumer Health business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results.
  • Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.
  • An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation.
  • A breach of privacy laws or unauthorized access, loss or misuse of personal data could have a negative impact to the Company’s business or reputation.
Management Discussion
  • For discussion on results of operations and financial condition pertaining to the fiscal years 2020 and 2019 see the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition.
  • In 2021, worldwide sales increased 13.6% to $93.8 billion as compared to an increase of 0.6% in 2020. These sales changes consisted of the following:
  • The net impact of acquisitions and divestitures on the worldwide sales growth was a negative impact of 0.6% in 2021 and a negative impact of 0.3% in 2020.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: Amax, analgesic, Aragon, argenx, ASPAC, Aurobindo, Belgium, Bergen, CAMC, Cataract, CPR, dispositive, EBSI, enforcing, Eugia, FASPRO, France, Genmab, Hetero, Kettering, mobility, neutral, Refractive, SE, SKI, Slight, Sloan, Slovenia, softer, Spain
Removed: Bayview, category, doubtful, dropped, hear, initiating, inspection, JAMP, long, MOTRIN, repayment, replied, short, stipulation, submitted, XR